BACKGROUND: The variation in ABO blood groups is reported to be associated with multiple diseases. Infliximab (IFX) has been widely used in the treatment of Crohn's disease (CD). We aim to investigate the distribution of ABO blood groups in Chinese patients with CD and to explore its impact on response to IFX. MATERIALS AND METHODS: Patients with CD were consecutively recruited to the study between 2007 and 2014. CD patients receiving IFX therapy were followed for at least two years. RESULTS: In 293 patients with CD, most patients (40.6%) had blood type O (119/293). The odds ratio (OR) of CD in blood type O patients was 1.06 (95%CI: 0.6-1.86; p=0.84) compared to all other blood types. Among those CD patients, 107 patients received IFX treatment. One year after the first course of IFX, a significant association was found between the overall ABO system and outcomes of IFX treatment (p<0.001). CD patients with blood type AB (OR=4.42, 95% CI: 1.04-18.76; p=0.044) were more likely to achieve mucosal healing, while CD patients with blood type A had a high risk of losing response (OR=0.38, 95% CI: 0.15-0.96; p=0.040). DISCUSSION: ABO blood groups are not associated with prevalence of CD. Patients with blood type AB had a better response to IFX while those with blood type A appeared to have a risk of losing response to IFX.
BACKGROUND: The variation in ABO blood groups is reported to be associated with multiple diseases. Infliximab (IFX) has been widely used in the treatment of Crohn's disease (CD). We aim to investigate the distribution of ABO blood groups in Chinese patients with CD and to explore its impact on response to IFX. MATERIALS AND METHODS:Patients with CD were consecutively recruited to the study between 2007 and 2014. CDpatients receiving IFX therapy were followed for at least two years. RESULTS: In 293 patients with CD, most patients (40.6%) had blood type O (119/293). The odds ratio (OR) of CD in blood type O patients was 1.06 (95%CI: 0.6-1.86; p=0.84) compared to all other blood types. Among those CDpatients, 107 patients received IFX treatment. One year after the first course of IFX, a significant association was found between the overall ABO system and outcomes of IFX treatment (p<0.001). CDpatients with blood type AB (OR=4.42, 95% CI: 1.04-18.76; p=0.044) were more likely to achieve mucosal healing, while CDpatients with blood type A had a high risk of losing response (OR=0.38, 95% CI: 0.15-0.96; p=0.040). DISCUSSION: ABO blood groups are not associated with prevalence of CD. Patients with blood type AB had a better response to IFX while those with blood type A appeared to have a risk of losing response to IFX.
Authors: M Luna-Chadid; J L Pérez Calle; J L Mendoza; M I Vera; A F Bermejo; F Sánchez; A López San Román; C Froilán; V González-Lara; J García-Paredes; I Fernández-Blanco; L Abreu; B Casis; J A Solís Herruzo; J P Gisbert; J Maté Jiménez Journal: Rev Esp Enferm Dig Date: 2004-06 Impact factor: 2.086
Authors: E Domènech; J Hinojosa; P Nos; E Garcia-Planella; E Cabré; I Bernal; M A Gassull Journal: Aliment Pharmacol Ther Date: 2005-12 Impact factor: 8.171
Authors: A S Parmar; N Alakulppi; P Paavola-Sakki; K Kurppa; L Halme; M Färkkilä; U Turunen; M Lappalainen; K Kontula; K Kaukinen; M Mäki; K Lindfors; J Partanen; P Sistonen; J Mättö; P Wacklin; P Saavalainen; E Einarsdottir Journal: Tissue Antigens Date: 2012-10-18
Authors: Diego Forni; Isabelle Cleynen; Marc Ferrante; Andrea Cassinotti; Rachele Cagliani; Sandro Ardizzone; Severine Vermeire; Maria Fichera; Marta Lombardini; Giovanni Maconi; Roberto de Franchis; Rosanna Asselta; Mara Biasin; Mario Clerici; Manuela Sironi Journal: J Crohns Colitis Date: 2013-11-21 Impact factor: 9.071
Authors: David Melzer; John R B Perry; Dena Hernandez; Anna-Maria Corsi; Kara Stevens; Ian Rafferty; Fulvio Lauretani; Anna Murray; J Raphael Gibbs; Giuseppe Paolisso; Sajjad Rafiq; Javier Simon-Sanchez; Hana Lango; Sonja Scholz; Michael N Weedon; Sampath Arepalli; Neil Rice; Nicole Washecka; Alison Hurst; Angela Britton; William Henley; Joyce van de Leemput; Rongling Li; Anne B Newman; Greg Tranah; Tamara Harris; Vijay Panicker; Colin Dayan; Amanda Bennett; Mark I McCarthy; Aimo Ruokonen; Marjo-Riitta Jarvelin; Jack Guralnik; Stefania Bandinelli; Timothy M Frayling; Andrew Singleton; Luigi Ferrucci Journal: PLoS Genet Date: 2008-05-09 Impact factor: 5.917